Phase II trial assessing efficacy, immunogenicity and tolerability of IR 208 [NeuroVax] in patients with relapsing-remitting multiple sclerosis.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2007
At a glance
- Drugs IR 902 (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 07 Mar 2007 Status changed from planning to in progress.
- 17 Oct 2006 New trial record.